Comparison of Clinical and Echocardiographic Outcomes After Surgical Redo Mitral Valve Replacement and Transcatheter Mitral Valve-in-Valve Therapy

Norihiko Kamioka, Vasilis Babaliaros, Michael Andrew Morse, Tiberio Frisoli, Stamatios Lerakis, Jose Miguel Iturbe, Jose Binongo, Frank Corrigan, Altayyeb Yousef, Patrick Gleason, John A. Wells, Hope Caughron, Andy Dong, Evelio Rodriguez, Bradley Leshnower, William O'Neill, Gaetano Paone, Marvin Eng, Robert Guyton, Peter C. Block & 1 others Adam Greenbaum

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives: There are minimal data regarding clinical outcomes and echocardiographic findings after transcatheter mitral valve-in-valve replacement (TMVR) compared with redo surgical mitral valve replacement (SMVR). Background: TMVR therapy has emerged as therapy for a degenerated bioprosthetic valve failure. Methods: The authors retrospectively identified patients with degenerated mitral bioprostheses who underwent redo SMVR or TMVR at 3 U.S. institutions. The authors compared clinical and echocardiographic outcomes of patients who had TMVR with those of patients who underwent redo SMVR. Results: Sixty-two patients underwent TMVR and 59 patients underwent SMVR during the study period. Mean age and the Society of Thoracic Surgeons Predicted Risk of Mortality (STS PROM) scores were significantly higher in patients with TMVR than in those with SMVR (age 74.9 ± 9.4 years vs. 63.7 ± 14.9 years; p < 0.001; STS PROM 12.7 ± 8.0% vs. 8.7 ± 10.1%; p < 0.0001). Total procedure time, intensive care unit hours, and post-procedure length of stay were all significantly shorter in the TMVR group. There was no difference in mortality at 1 year between the 2 groups (TMVR 11.3% vs. SMVR 11.9%; p = 0.92). Mean mitral valve pressure gradient and the grade of mitral regurgitation (MR) were similar between the TMVR group and the SMVR group (mitral valve pressure gradient 7.1 ± 2.5 mm Hg vs. 6.5 ± 2.5 mm Hg; p = 0.42; MR [≥moderate] 3.8% vs. 5.6%; p = 1.00) at 30 days. At 1 year, the mitral valve pressure gradient was higher in the TMVR group (TMVR 7.2 ± 2.7 vs. SMVR 5.5 ± 1.8; p = 0.01), although there was no difference in the grade of MR. Conclusions: Despite the higher STS PROM in TMVR patients, there was no difference in 1-year mortality between the TMVR and SMVR groups. Echocardiographic findings after TMVR were similar to SMVR at 30 days. There was a statistically significant difference in mitral gradient at 1 year, though this is likely not clinically important. TMVR may be an alternative to SMVR in patients with previous mitral bioprosthetic valves.

Original languageEnglish (US)
Pages (from-to)1131-1138
Number of pages8
JournalJACC: Cardiovascular Interventions
Volume11
Issue number12
DOIs
StatePublished - Jun 25 2018
Externally publishedYes

Fingerprint

Mitral Valve
Surgical Instruments
Therapeutics
Mortality
Mitral Valve Insufficiency
Pressure
Thorax

Keywords

  • mitral valve replacement
  • redo
  • valve-in-valve

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Comparison of Clinical and Echocardiographic Outcomes After Surgical Redo Mitral Valve Replacement and Transcatheter Mitral Valve-in-Valve Therapy. / Kamioka, Norihiko; Babaliaros, Vasilis; Morse, Michael Andrew; Frisoli, Tiberio; Lerakis, Stamatios; Iturbe, Jose Miguel; Binongo, Jose; Corrigan, Frank; Yousef, Altayyeb; Gleason, Patrick; Wells, John A.; Caughron, Hope; Dong, Andy; Rodriguez, Evelio; Leshnower, Bradley; O'Neill, William; Paone, Gaetano; Eng, Marvin; Guyton, Robert; Block, Peter C.; Greenbaum, Adam.

In: JACC: Cardiovascular Interventions, Vol. 11, No. 12, 25.06.2018, p. 1131-1138.

Research output: Contribution to journalArticle

Kamioka, N, Babaliaros, V, Morse, MA, Frisoli, T, Lerakis, S, Iturbe, JM, Binongo, J, Corrigan, F, Yousef, A, Gleason, P, Wells, JA, Caughron, H, Dong, A, Rodriguez, E, Leshnower, B, O'Neill, W, Paone, G, Eng, M, Guyton, R, Block, PC & Greenbaum, A 2018, 'Comparison of Clinical and Echocardiographic Outcomes After Surgical Redo Mitral Valve Replacement and Transcatheter Mitral Valve-in-Valve Therapy', JACC: Cardiovascular Interventions, vol. 11, no. 12, pp. 1131-1138. https://doi.org/10.1016/j.jcin.2018.03.011
Kamioka, Norihiko ; Babaliaros, Vasilis ; Morse, Michael Andrew ; Frisoli, Tiberio ; Lerakis, Stamatios ; Iturbe, Jose Miguel ; Binongo, Jose ; Corrigan, Frank ; Yousef, Altayyeb ; Gleason, Patrick ; Wells, John A. ; Caughron, Hope ; Dong, Andy ; Rodriguez, Evelio ; Leshnower, Bradley ; O'Neill, William ; Paone, Gaetano ; Eng, Marvin ; Guyton, Robert ; Block, Peter C. ; Greenbaum, Adam. / Comparison of Clinical and Echocardiographic Outcomes After Surgical Redo Mitral Valve Replacement and Transcatheter Mitral Valve-in-Valve Therapy. In: JACC: Cardiovascular Interventions. 2018 ; Vol. 11, No. 12. pp. 1131-1138.
@article{756111758fce43bb8ba29bb985cb3ed5,
title = "Comparison of Clinical and Echocardiographic Outcomes After Surgical Redo Mitral Valve Replacement and Transcatheter Mitral Valve-in-Valve Therapy",
abstract = "Objectives: There are minimal data regarding clinical outcomes and echocardiographic findings after transcatheter mitral valve-in-valve replacement (TMVR) compared with redo surgical mitral valve replacement (SMVR). Background: TMVR therapy has emerged as therapy for a degenerated bioprosthetic valve failure. Methods: The authors retrospectively identified patients with degenerated mitral bioprostheses who underwent redo SMVR or TMVR at 3 U.S. institutions. The authors compared clinical and echocardiographic outcomes of patients who had TMVR with those of patients who underwent redo SMVR. Results: Sixty-two patients underwent TMVR and 59 patients underwent SMVR during the study period. Mean age and the Society of Thoracic Surgeons Predicted Risk of Mortality (STS PROM) scores were significantly higher in patients with TMVR than in those with SMVR (age 74.9 ± 9.4 years vs. 63.7 ± 14.9 years; p < 0.001; STS PROM 12.7 ± 8.0{\%} vs. 8.7 ± 10.1{\%}; p < 0.0001). Total procedure time, intensive care unit hours, and post-procedure length of stay were all significantly shorter in the TMVR group. There was no difference in mortality at 1 year between the 2 groups (TMVR 11.3{\%} vs. SMVR 11.9{\%}; p = 0.92). Mean mitral valve pressure gradient and the grade of mitral regurgitation (MR) were similar between the TMVR group and the SMVR group (mitral valve pressure gradient 7.1 ± 2.5 mm Hg vs. 6.5 ± 2.5 mm Hg; p = 0.42; MR [≥moderate] 3.8{\%} vs. 5.6{\%}; p = 1.00) at 30 days. At 1 year, the mitral valve pressure gradient was higher in the TMVR group (TMVR 7.2 ± 2.7 vs. SMVR 5.5 ± 1.8; p = 0.01), although there was no difference in the grade of MR. Conclusions: Despite the higher STS PROM in TMVR patients, there was no difference in 1-year mortality between the TMVR and SMVR groups. Echocardiographic findings after TMVR were similar to SMVR at 30 days. There was a statistically significant difference in mitral gradient at 1 year, though this is likely not clinically important. TMVR may be an alternative to SMVR in patients with previous mitral bioprosthetic valves.",
keywords = "mitral valve replacement, redo, valve-in-valve",
author = "Norihiko Kamioka and Vasilis Babaliaros and Morse, {Michael Andrew} and Tiberio Frisoli and Stamatios Lerakis and Iturbe, {Jose Miguel} and Jose Binongo and Frank Corrigan and Altayyeb Yousef and Patrick Gleason and Wells, {John A.} and Hope Caughron and Andy Dong and Evelio Rodriguez and Bradley Leshnower and William O'Neill and Gaetano Paone and Marvin Eng and Robert Guyton and Block, {Peter C.} and Adam Greenbaum",
year = "2018",
month = "6",
day = "25",
doi = "10.1016/j.jcin.2018.03.011",
language = "English (US)",
volume = "11",
pages = "1131--1138",
journal = "JACC. Cardiovascular interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Comparison of Clinical and Echocardiographic Outcomes After Surgical Redo Mitral Valve Replacement and Transcatheter Mitral Valve-in-Valve Therapy

AU - Kamioka, Norihiko

AU - Babaliaros, Vasilis

AU - Morse, Michael Andrew

AU - Frisoli, Tiberio

AU - Lerakis, Stamatios

AU - Iturbe, Jose Miguel

AU - Binongo, Jose

AU - Corrigan, Frank

AU - Yousef, Altayyeb

AU - Gleason, Patrick

AU - Wells, John A.

AU - Caughron, Hope

AU - Dong, Andy

AU - Rodriguez, Evelio

AU - Leshnower, Bradley

AU - O'Neill, William

AU - Paone, Gaetano

AU - Eng, Marvin

AU - Guyton, Robert

AU - Block, Peter C.

AU - Greenbaum, Adam

PY - 2018/6/25

Y1 - 2018/6/25

N2 - Objectives: There are minimal data regarding clinical outcomes and echocardiographic findings after transcatheter mitral valve-in-valve replacement (TMVR) compared with redo surgical mitral valve replacement (SMVR). Background: TMVR therapy has emerged as therapy for a degenerated bioprosthetic valve failure. Methods: The authors retrospectively identified patients with degenerated mitral bioprostheses who underwent redo SMVR or TMVR at 3 U.S. institutions. The authors compared clinical and echocardiographic outcomes of patients who had TMVR with those of patients who underwent redo SMVR. Results: Sixty-two patients underwent TMVR and 59 patients underwent SMVR during the study period. Mean age and the Society of Thoracic Surgeons Predicted Risk of Mortality (STS PROM) scores were significantly higher in patients with TMVR than in those with SMVR (age 74.9 ± 9.4 years vs. 63.7 ± 14.9 years; p < 0.001; STS PROM 12.7 ± 8.0% vs. 8.7 ± 10.1%; p < 0.0001). Total procedure time, intensive care unit hours, and post-procedure length of stay were all significantly shorter in the TMVR group. There was no difference in mortality at 1 year between the 2 groups (TMVR 11.3% vs. SMVR 11.9%; p = 0.92). Mean mitral valve pressure gradient and the grade of mitral regurgitation (MR) were similar between the TMVR group and the SMVR group (mitral valve pressure gradient 7.1 ± 2.5 mm Hg vs. 6.5 ± 2.5 mm Hg; p = 0.42; MR [≥moderate] 3.8% vs. 5.6%; p = 1.00) at 30 days. At 1 year, the mitral valve pressure gradient was higher in the TMVR group (TMVR 7.2 ± 2.7 vs. SMVR 5.5 ± 1.8; p = 0.01), although there was no difference in the grade of MR. Conclusions: Despite the higher STS PROM in TMVR patients, there was no difference in 1-year mortality between the TMVR and SMVR groups. Echocardiographic findings after TMVR were similar to SMVR at 30 days. There was a statistically significant difference in mitral gradient at 1 year, though this is likely not clinically important. TMVR may be an alternative to SMVR in patients with previous mitral bioprosthetic valves.

AB - Objectives: There are minimal data regarding clinical outcomes and echocardiographic findings after transcatheter mitral valve-in-valve replacement (TMVR) compared with redo surgical mitral valve replacement (SMVR). Background: TMVR therapy has emerged as therapy for a degenerated bioprosthetic valve failure. Methods: The authors retrospectively identified patients with degenerated mitral bioprostheses who underwent redo SMVR or TMVR at 3 U.S. institutions. The authors compared clinical and echocardiographic outcomes of patients who had TMVR with those of patients who underwent redo SMVR. Results: Sixty-two patients underwent TMVR and 59 patients underwent SMVR during the study period. Mean age and the Society of Thoracic Surgeons Predicted Risk of Mortality (STS PROM) scores were significantly higher in patients with TMVR than in those with SMVR (age 74.9 ± 9.4 years vs. 63.7 ± 14.9 years; p < 0.001; STS PROM 12.7 ± 8.0% vs. 8.7 ± 10.1%; p < 0.0001). Total procedure time, intensive care unit hours, and post-procedure length of stay were all significantly shorter in the TMVR group. There was no difference in mortality at 1 year between the 2 groups (TMVR 11.3% vs. SMVR 11.9%; p = 0.92). Mean mitral valve pressure gradient and the grade of mitral regurgitation (MR) were similar between the TMVR group and the SMVR group (mitral valve pressure gradient 7.1 ± 2.5 mm Hg vs. 6.5 ± 2.5 mm Hg; p = 0.42; MR [≥moderate] 3.8% vs. 5.6%; p = 1.00) at 30 days. At 1 year, the mitral valve pressure gradient was higher in the TMVR group (TMVR 7.2 ± 2.7 vs. SMVR 5.5 ± 1.8; p = 0.01), although there was no difference in the grade of MR. Conclusions: Despite the higher STS PROM in TMVR patients, there was no difference in 1-year mortality between the TMVR and SMVR groups. Echocardiographic findings after TMVR were similar to SMVR at 30 days. There was a statistically significant difference in mitral gradient at 1 year, though this is likely not clinically important. TMVR may be an alternative to SMVR in patients with previous mitral bioprosthetic valves.

KW - mitral valve replacement

KW - redo

KW - valve-in-valve

UR - http://www.scopus.com/inward/record.url?scp=85048613213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048613213&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2018.03.011

DO - 10.1016/j.jcin.2018.03.011

M3 - Article

VL - 11

SP - 1131

EP - 1138

JO - JACC. Cardiovascular interventions

JF - JACC. Cardiovascular interventions

SN - 1936-8798

IS - 12

ER -